Please ensure Javascript is enabled for purposes of website accessibility

Will Intuitive Surgical Be a Trillion-Dollar Stock by 2031?

By Adria Cimino - Jun 21, 2021 at 6:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company dominates a growing area in healthcare.

A lot can happen in 10 years. For instance, online retail giant saw its market cap soar more than 1,900% to reach $1.7 trillion. And longtime shareholders reaped a big reward: a 1,700% gain in the stock price. Of course, we all would like to find the next trillion-dollar story. As long-term investors, we don't mind buying now and sticking around for several years.

So, let's turn to the healthcare sector and take a look at a growth stock with strong market leadership. I'm talking about Intuitive Surgical (ISRG -0.05%). The company is the world's leading maker of robotic surgical systems. Can this player in a growing and innovative market become a trillion-dollar stock ten years from now?

Three investors in an office gather around a desk to look at a computer.

Image source: Getty Images.

Trillion-dollar tech companies

First, it's important to note that so far, the only companies that have reached the trillion-dollar valuation mark are in the technology sector. The biggest healthcare company is Johnson & Johnson, weighing in with a market cap of more than $440 billion. So, we can see that arriving at $1 trillion isn't an easy-to-reach goal.

Today, Intuitive's market cap totals about $104 billion. It's climbed 674% over the past decade to reach that level. To reach $1 trillion from today's level, Intuitive's market cap would have to grow more than 861%. Can that be done?

An increase in market cap happens in two ways. A company issues new shares. Or, simply, the value of a company's stock increases. A combination of these two also does the trick.

Today's trillion-dollar companies don't have a greatly higher number of outstanding shares now compared with a decade ago. Some even have fewer. They have, however, boosted revenue in the triple digits.

AMZN Shares Outstanding Chart

AMZN Shares Outstanding data by YCharts

A good revenue track record

Intuitive has a good track record when it comes to revenue. The company's annual revenue has climbed 148% to more than $4 billion over the past decade. But this level of revenue is much lower than that of our trillion-dollar companies. They report annual revenue in the hundreds of billions.

AMZN Revenue (Annual) Chart

AMZN Revenue (Annual) data by YCharts

Still, strong revenue growth could result in big share gains -- even if that revenue isn't at the level of technology industry giants. And that, in turn, will lift market cap.

Now, let's take a look at revenue growth potential. Intuitive holds more than 79% of the robotic surgery market, according to a BIS Research report. The company recently said its number of installed systems totals more than 6,100 worldwide. And procedures using the flagship Da Vinci surgical system increased 16% in the first quarter year over year.

The coronavirus pandemic put the brakes on Intuitive's progress over the past year. That's because many nonessential surgeries were postponed. Intuitive's growth is recovering -- and it should further improve once the crisis is over.

So, does this put Intuitive on the path to $1 trillion in market value?

Probably not. Revenue gains and procedure growth will boost the share price. But I don't expect the momentum to be strong enough to reach the $1 trillion level.

Intuitive's dominance in the market should help it to hold onto a big portion of the market for a while and continue to grow. But it is possible rivals will make inroads over the coming years. BIS Research even predicts Intuitive's market share may fall to about 52% by 2031. That could mean slower revenue growth at that point. And that could limit share price gains. BIS expects the value of the entire robotics surgery market, at a 10% compound annual growth rate, will reach more than $16 billion in a decade.

Even if BIS' scenario plays out, I'm still optimistic about Intuitive over the long term. The company will generate billions in revenue. Relationships it already has with surgeons and its innovation may keep it a step ahead of rivals. So, it's a great stock for any healthcare portfolio -- even if its market value stays under the $1 trillion mark.

John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Teresa Kersten, an employee of LinkedIn, a Microsoft subsidiary, is a member of The Motley Fool's board of directors. Adria Cimino owns shares of Amazon. The Motley Fool owns shares of and recommends Alphabet (A shares), Alphabet (C shares), Amazon, Apple, Intuitive Surgical, and Microsoft. The Motley Fool recommends Johnson & Johnson and recommends the following options: long January 2022 $1,920 calls on Amazon, long January 2022 $580 calls on Intuitive Surgical, long March 2023 $120 calls on Apple, short January 2022 $1,940 calls on Amazon, short January 2022 $600 calls on Intuitive Surgical, and short March 2023 $130 calls on Apple. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Intuitive Surgical, Inc. Stock Quote
Intuitive Surgical, Inc.
$238.26 (-0.05%) $0.11
Apple Inc. Stock Quote
Apple Inc.
$173.19 (0.63%) $1.09
Microsoft Corporation Stock Quote
Microsoft Corporation
$293.47 (0.53%) $1.56
Alphabet Inc. Stock Quote
Alphabet Inc.
$122.08 (0.33%) $0.40
Johnson & Johnson Stock Quote
Johnson & Johnson
$166.09 (0.48%) $0.79, Inc. Stock Quote, Inc.
$143.18 (-0.26%) $0.37

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.